[Ascitic fluid: benignancy and malignancy parameters].
Fluixá Carrascosa
F
F
Servicio de Medicina Interna, Hospital Francesc de Borja, Gandia, Valencia.
Rull Segura
S
S
Devesa Jorda
F
F
Martín Estruch
A
A
Tur Cotaina
M D
MD
Borghol Hariri
A
A
Pérez Serra
J
J
D000418:Albumins / Q000032:analysis; D001202:Ascitic Fluid / Q000737:chemistry* / Q000166:cytology / Q000201:enzymology; D014408:Biomarkers, Tumor / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002784:Cholesterol / Q000032:analysis; D002802:Cholinesterases / Q000032:analysis; D003365:Costs and Cost Analysis; D003937:Diagnosis, Differential; D005353:Fibronectins / Q000032:analysis; D006466:Hemopexin / Q000032:analysis; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D011506:Proteins / Q000032:analysis; D012680:Sensitivity and Specificity; D000515:alpha 1-Antitrypsin / Q000032:analysis; D000509:alpha-Fetoproteins / Q000032:analysis
D000418:Albumins; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D005353:Fibronectins; D011506:Proteins; D000515:alpha 1-Antitrypsin; D000509:alpha-Fetoproteins; D006466:Hemopexin; D002784:Cholesterol; D007770:L-Lactate Dehydrogenase; D002802:Cholinesterases